How much profit has Allovir made this year?
Allovir has made -58.45 M USD this year.
Allovir Net Income 2024
Allovir Net Income
-58.45 M USD
Ticker
ALVR
ISIN
US0198181036
WKN
A2QAMR
In 2024, Allovir's profit amounted to -58.45 M USD, a -69.31% increase from the -190.42 M USD profit recorded in the previous year.
The Allovir Net Income history
| YEAR | NET INCOME (undefined USD) |
|---|---|
| 2029e | - |
| 2028e | - |
| 2027e | - |
| 2026e | - |
| 2025e | - |
| 2024e | - |
| 2023 | - |
| 2022 | - |
| 2021 | - |
| 2020 | - |
| 2019 | - |
| 2018 | - |
Allovir Revenue, EBIT, Net Income US0198181036 · A2QAMR
3 years
5 years
10 years
25 Years
Max
Revenue
EBIT
Net Income
Details
Revenue, EBIT and Profit
ⓘUnderstanding Revenue, EBIT, and Income
Gain insights into Allovir, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Allovir from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Allovir’s net earnings, an ultimate measure of its financial health and profitability.
Yearly Analysis and Comparisons
Observe the yearly bars to understand the annual performance and growth of Allovir. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
Utilizing Expectations for Investment
The expected values for the forthcoming years offer investors a glimpse into Allovir’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Investment Insights
Leveraging the comparison between Revenue and EBIT helps in assessing Allovir’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Allovir’s growth potential.
Allovir Revenue, EBIT and net profit per share
| Date | Allovir Revenue | Allovir EBIT | Allovir Net Income |
|---|---|---|---|
| 2029e | 0 undefined | 0 undefined | 0 undefined |
| 2028e | 0 undefined | -58.38 M undefined | 0 undefined |
| 2027e | 0 undefined | -57.8 M undefined | 0 undefined |
| 2026e | 0 undefined | -73.72 M undefined | -51.78 M undefined |
| 2025e | 0 undefined | -39.67 M undefined | -34.13 M undefined |
| 2024e | 0 undefined | -65.03 M undefined | -58.45 M undefined |
| 2023 | 0 undefined | -181.33 M undefined | -190.42 M undefined |
| 2022 | 0 undefined | -171.2 M undefined | -168.71 M undefined |
| 2021 | 0 undefined | -169.82 M undefined | -171.96 M undefined |
| 2020 | 0 undefined | -71.31 M undefined | -69.78 M undefined |
| 2019 | 170,000 undefined | -26.7 M undefined | -23.84 M undefined |
| 2018 | 1.14 M undefined | -3.6 M undefined | -8.16 M undefined |
| Revenue | EBIT | Net Income | |
|---|---|---|---|
| 2018 | 1.14 M USD | -3.6 M USD | -8.16 M USD |
| 2019 | 170,000 USD | -26.7 M USD | -23.84 M USD |
| 2020 | 0 USD | -71.31 M USD | -69.78 M USD |
| 2021 | 0 USD | -169.82 M USD | -171.96 M USD |
| 2022 | 0 USD | -171.2 M USD | -168.71 M USD |
| 2023 | 0 USD | -181.33 M USD | -190.42 M USD |
| 2024e | 0 USD | -65.03 M USD | -58.45 M USD |
| 2025e | 0 USD | -39.67 M USD | -34.13 M USD |
| 2026e | 0 USD | -73.72 M USD | -51.78 M USD |
| 2027e | 0 USD | -57.8 M USD | 0 USD |
| 2028e | 0 USD | -58.38 M USD | 0 USD |
| 2029e | 0 USD | 0 USD | 0 USD |
Allovir stock margins US0198181036 · A2QAMR
The Allovir margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Allovir. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Allovir.
3 years
5 years
10 years
25 Years
Max
Gross margin
EBIT margin
Profit margin
Details
Margin
ⓘUnderstanding Gross Margin
The gross margin, expressed as a percentage, delineates the gross profit made from the Allovir's sales revenue. A higher gross margin percentage indicates that the Allovir retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT Margin Analysis
EBIT margin represents the Allovir's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
Revenue Margin Insights
The revenue margin demonstrates the Allovir's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Allovir's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
Interpreting Expectations
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Allovir. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparative Analysis
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Allovir's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
Allovir Margin History
| Allovir Gross margin | Allovir Profit margin | Allovir EBIT margin | Allovir Profit margin |
|---|---|---|---|
| 2029e | 0 % | 0 % | 0 % |
| 2028e | 0 % | 0 % | 0 % |
| 2027e | 0 % | 0 % | 0 % |
| 2026e | 0 % | 0 % | 0 % |
| 2025e | 0 % | 0 % | 0 % |
| 2024e | 0 % | 0 % | 0 % |
| 2023 | 0 % | 0 % | 0 % |
| 2022 | 0 % | 0 % | 0 % |
| 2021 | 0 % | 0 % | 0 % |
| 2020 | 0 % | 0 % | 0 % |
| 2019 | 0 % | -15,705.88 % | -14,023.53 % |
| 2018 | 0 % | -315.79 % | -715.79 % |
| Gross margin | EBIT margin | Profit margin | |
|---|---|---|---|
| 2018 | 0 % | -315.79 % | -715.79 % |
| 2019 | 0 % | -15,705.88 % | -14,023.53 % |
| 2020 | 0 % | 0 % | 0 % |
| 2021 | 0 % | 0 % | 0 % |
| 2022 | 0 % | 0 % | 0 % |
| 2023 | 0 % | 0 % | 0 % |
| 2024e | 0 % | 0 % | 0 % |
| 2025e | 0 % | 0 % | 0 % |
| 2026e | 0 % | 0 % | 0 % |
| 2027e | 0 % | 0 % | 0 % |
| 2028e | 0 % | 0 % | 0 % |
| 2029e | 0 % | 0 % | 0 % |
Allovir Aktienanalyse
What does Allovir do?
Allovir Inc was founded in 2013 in Cambridge, Massachusetts and is a biopharmaceutical company specializing in the development and commercialization of cellular immunotherapies for viral infections. The idea behind the founding of Allovir was to develop a new generation of immunotherapies with the potential to treat virus-related diseases that were previously difficult to treat. Allovir's business model is based on the development and commercialization of cellular immunotherapies that rely on the patient's immune system to fight infections. The company focuses on two main areas: infectious diseases and cancer. Within these areas, Allovir focuses on the development of therapies for severe viral infections such as BK virus, cytomegalovirus (CMV), and adenovirus, as well as the development of therapies to combat cancer. Allovir's first product candidates are Viral Associated Diseases (VAD) cell therapies developed to treat infections caused by BK virus, CMV, and adenovirus. These therapies consist of virus-specific T cells that are extracted from the patient's blood, amplified and activated in the laboratory, and then reintroduced into the patient where they can directly attack and eliminate the virus. Another promising product that Allovir is currently developing is ALVR106, a cellular immunotherapy for the treatment of cancer. ALVR106 is a CAR-T cell therapy candidate that aims to target HER2-positive solid tumors. The active ingredient is based on certain T cells that have been modified to specifically recognize and attack tumor-specific antigens. Allovir has conducted several successful clinical trials in recent years and has achieved promising results. Significant progress was observed in a clinical trial for the treatment of BK virus infections in kidney transplant patients. Therapy with virus-specific T cells resulted in a significant reduction in viral load and improvement in kidney function. Allovir's therapy also showed promising results in a Phase 2 trial for the treatment of CMV in bone marrow transplant patients. Allovir has established a strong position in the field of cellular immunotherapies for viral infections in recent years. The company has built an impressive research and development platform and has an experienced team of researchers and developers. The clinical results of Allovir's products demonstrate a high potential for future developments, and the company is expected to continue to grow and innovate in the coming years. Allovir ist eines der beliebtesten Unternehmen auf Eulerpool.com.Net Income Details
Understanding Allovir's Profit Margins
The profit margins of Allovir represent the net income earned after deducting all operational expenses, costs, and taxes from the revenue. This figure is a clear indicator of Allovir's financial health, operational efficiency, and profitability. Higher profit margins signify better cost management and income generation capabilities.
Year-to-Year Comparison
Evaluating Allovir's profit on a yearly basis can offer significant insights into its financial growth, stability, and trends. A consistent increase in profit suggests improved operational efficiency, cost management, or increased revenue, while a decrease may indicate rising costs, declining sales, or operational challenges.
Impact on Investments
Allovir's profit figures are critical for investors who are aiming to understand the company's financial standing and future growth prospects. Increased profits often lead to higher stock valuations, boosting investor confidence and attracting more investments.
Interpreting Profit Fluctuations
When Allovir’s profit increases, it often indicates enhanced operational efficiency or increased sales. In contrast, a decline in profit can signal operational inefficiencies, increased costs, or competitive pressures, necessitating strategic interventions to boost profitability.
Frequently Asked Questions about Allovir stock
How has the profit developed compared to last year?
The profit has increased by -69.31% compared to last year fallen
What impact do the earnings have on the shareholders?
An increase in earnings is usually seen as a positive indicator for shareholders as it means that the company is generating profits.
How does Allovir publish its earnings?
Allovir publishes its earnings in the form of quarterly or annual reports.
Which financial indicators are included in the quarterly or annual reports?
The quarterly or annual reports contain information about sales and profit, cash flow, balance sheet, and other fundamentals.
Why is it important for investors to know the earnings of Allovir?
The profits of Allovir are an important indicator of the financial health of the company and can help investors decide whether they want to invest in the company or not.
How can one learn more about the earnings of Allovir?
You can learn more about the earnings of Allovir by reviewing the quarterly or annual reports or following the company presentations.
How much dividend does Allovir pay?
Over the past 12 months, Allovir paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Allovir is expected to pay a dividend of 0 USD.
What is the dividend yield of Allovir?
The current dividend yield of Allovir is .
When does Allovir pay dividends?
Allovir pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Allovir?
Allovir paid dividends every year for the past 0 years.
What is the dividend of Allovir?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Allovir located?
Allovir is assigned to the 'Health' sector.
Wann musste ich die Aktien von Allovir kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Allovir from 11/18/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 11/18/2024.
When did Allovir pay the last dividend?
The last dividend was paid out on 11/18/2024.
What was the dividend of Allovir in the year 2023?
In the year 2023, Allovir distributed 0 USD as dividends.
In which currency does Allovir pay out the dividend?
The dividends of Allovir are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Allovir
Our stock analysis for Allovir Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Allovir Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
